Literature DB >> 21419475

Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma.

Xin-Xin Wang1, Zhengmao Zhu, Dan Su, Ting Lei, Xiao Wu, Yu Fan, Xin Li, Jing Zhao, Liya Fu, Jin-Tang Dong, Li Fu.   

Abstract

Leucine zipper putative tumor suppressor 1 is down-regulated by promoter methylation, but not frequently, in human malignancies, including breast cancer. Recent studies suggest that leucine zipper putative tumor suppressor 1 is a candidate for the metastasis modifier locus on human chromosome 8p in melanoma. In this study, we evaluated whether leucine zipper putative tumor suppressor 1 plays a role in breast cancer metastasis. We found that leucine zipper putative tumor suppressor 1 protein expression was significantly reduced or absent in a series of 340 invasive breast carcinomas compared to normal breast tissue. Lower levels of leucine zipper putative tumor suppressor 1 correlated with high histologic grade, lymph node metastasis, and poor prognosis. Functional studies demonstrated that ectopic expression of leucine zipper putative tumor suppressor 1 in the highly malignant MDA-MB-231 breast cancer cell line suppressed cell proliferation, migration, and invasion in vitro. Expression of leucine zipper putative tumor suppressor 1 in MDA-MB-231 cells also induced a series of changes that are characteristic of mesenchymal-to-epithelial transition, including phenotypic change, up-regulation of epithelial markers E-cadherin, β-catenin, and cytokeratin and down-regulation of the mesenchymal marker vimentin. Expression of leucine zipper putative tumor suppressor 1 also repressed the transcription of Slug and Snail, which both repress E-cadherin expression during epithelial-to-mesenchymal transition. These findings suggest that epithelial-to-mesenchymal transition likely inhibits breast cancer metastasis by intervening in epithelial-to-mesenchymal transition in breast cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21419475     DOI: 10.1016/j.humpath.2010.12.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells.

Authors:  B P Huderson; T T Duplessis; C C Williams; H C Seger; C G Marsden; K J Pouey; S M Hill; B G Rowan
Journal:  Endocrinology       Date:  2012-06-25       Impact factor: 4.736

2.  FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT.

Authors:  Jian Feng; Xuesong Zhang; Huijun Zhu; Xudong Wang; Songshi Ni; Jianfei Huang
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

3.  Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer.

Authors:  Matthias Wielscher; Willy Liou; Walter Pulverer; Christian F Singer; Christine Rappaport-Fuerhauser; Daniela Kandioler; Gerda Egger; Andreas Weinhäusel
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

4.  MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1.

Authors:  Ching-Wen Lin; Yih-Leong Chang; Yu-Chiuan Chang; Jau-Chen Lin; Chun-Chi Chen; Szu-Hua Pan; Chen-Tu Wu; Hsuan-Yu Chen; Shuenn-Chen Yang; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.

Authors:  Ewa Mrózek; Rachel Layman; Bhuvaneswari Ramaswamy; Maryam Lustberg; Andrea Vecchione; Michael V Knopp; Charles L Shapiro
Journal:  Clin Breast Cancer       Date:  2014-02-20       Impact factor: 3.225

6.  Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum.

Authors:  Iain L O Buxton; Nucharee Yokdang
Journal:  Cancers (Basel)       Date:  2011-09       Impact factor: 6.639

7.  MicroRNA-135b Regulates Leucine Zipper Tumor Suppressor 1 in Cutaneous Squamous Cell Carcinoma.

Authors:  Edit B Olasz; Lauren N Seline; Ashley M Schock; Nathan E Duncan; Argelia Lopez; Jozef Lazar; Michael J Flister; Yan Lu; Pengyuan Liu; Olayemi Sokumbi; Catherine A Harwood; Charlotte M Proby; Marcy Neuburg; Zelmira Lazarova
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

8.  Loss of Leucine Zipper Putative Tumor Suppressor 1 (LZTS1) Expression Contributes to Lymph Node Metastasis of Breast Invasive Micropapillary Carcinoma.

Authors:  Xin-Xin Wang; Bing-Bing Liu; Xiao Wu; Dan Su; Zhengmao Zhu; Li Fu
Journal:  Pathol Oncol Res       Date:  2015-03-27       Impact factor: 3.201

9.  LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.

Authors:  Francesca Lovat; Hideshi Ishii; Monica Schiappacassi; Matteo Fassan; Mattia Barbareschi; Enzo Galligioni; Pierluigi Gasparini; Gustavo Baldassarre; Carlo M Croce; Andrea Vecchione
Journal:  Oncotarget       Date:  2014-02-28

10.  Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.

Authors:  Nader Al Nakouzi; Sophie Cotteret; Frédéric Commo; Catherine Gaudin; Shanna Rajpar; Philippe Dessen; Philippe Vielh; Karim Fizazi; Anne Chauchereau
Journal:  Oncotarget       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.